Endothelial keratoplasty: indications and outcomes in a tertiary care center in Lebanon

内皮角膜移植术:黎巴嫩一家三级医疗中心的适应症和结果

阅读:1

Abstract

OBJECTIVE: This study aims to assess the indications and outcomes of Descemet membrane endothelial keratoplasty (DMEK) surgeries in Lebanon, where tissues are imported. Focusing on visual acuity (VA) and central corneal thickness (CCT). METHODS: This retrospective chart review analyzed 86 DMEK surgeries performed on 78 patients between 2016 and 2023, examining CCT and VA measured preoperatively and up to one-year post-DMEK. Variables of interest included the rate of rebubbling, intraocular pressure (IOP), tissue preparation methods (preloaded, surgeon-prepared, or pre-stripped/precut tissue), donor age, donor endothelial cell count, time from death to preservation, time from preservation to surgery, and time from death to transplant. The goal was to explore the relationships between these variables and the clinical outcomes. RESULTS: The most common indication for DMEK was pseudophakic or aphakic bullous keratopathy (PBK), followed by graft failure and Fuchs' endothelial corneal dystrophy (FECD). Significant improvements in VA and CCT were observed postoperatively (p < 0.001 and p ≤ 0.015 respectively). The mean IOP was 16.8 mmHg at baseline and 17.2 mmHg at 1 year post-operatively. The mean LogMAR score was 1.46 ± 0.16 at baseline, improving to 0.87 ± 0.21 at the 1-year follow-up. The rebubbling rate was 28.7%. Patients who required rebubbling had significantly higher central corneal thickness (CCT) during the first month (p = 0.027), but this difference was not observed over the course of the entire year. However, a notable incidence of postoperative new onset elevation in IOP was documented, affecting approximately 36.5% of patients. CONCLUSION: Despite challenges posed by limited resources and economic constraints in Lebanon, DMEK surgery has shown promising outcomes in improving VA and CCT. Vigilant monitoring and management of postoperative complications, particularly elevated IOP, is essential. Addressing systemic barriers to healthcare access and enhancing corneal transplantation infrastructure are crucial for ensuring equitable delivery of advanced ophthalmic care in resource-limited settings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。